Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hip PRO Pilot
NCT05775965Phase 2Recruiting
- Sponsor
- University of Calgary
- Start
- May 2024
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rivaroxaban, aspirin in venous thromboembolism (VTE), sponsored by University of Calgary. Started May 2024; status: recruiting.
02
Drugs
rivaroxabanaspirin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05775965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775965.